Goodrx (GDRX) analyst forecast and price target
Analyst forecast
Consensus of 15 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Underweight | $4.00 from $3.00 | Aug 21, 2026 |
| UBS | Maintained | Neutral | $3.75 from $2.50 | Aug 13, 2026 |
| TD Cowen | Maintained | Buy | $5.00 from $4.00 | Aug 11, 2026 |
| Citigroup | Maintained | Buy | $5.00 from $4.00 | Aug 11, 2026 |
| Wells Fargo | Maintained | Overweight | $5.00 from $3.50 | Aug 7, 2026 |
| Citigroup | Maintained | Buy | $4.00 from $3.50 | May 14, 2026 |
| TD Cowen | Maintained | Buy | $4.00 from $3.00 | May 11, 2026 |
| Wells Fargo | Maintained | Overweight | $3.50 from $7.00 | Mar 4, 2026 |
| Citigroup | Maintained | Buy | $3.50 from $4.50 | Mar 3, 2026 |
| Goldman Sachs | Maintained | Neutral | $2.50 from $4.00 | Mar 2, 2026 |
| JP Morgan | Downgraded | Overweight → Neutral | — | Feb 27, 2026 |
| Mizuho | Maintained | Neutral | $3.00 from $4.00 | Feb 27, 2026 |
| Jefferies | Downgraded | Buy → Hold | $2.75 from $5.25 | Jan 22, 2026 |
| Citigroup | Maintained | Buy | $4.50 from $5.00 | Jan 9, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $4.00 from $5.00 | Dec 18, 2025 |
| Barclays | Initiated Coverage | Underweight | $3.00 | Dec 9, 2025 |
| JP Morgan | Maintained | Overweight | $5.00 from $6.00 | Nov 11, 2025 |
| TD Cowen | Maintained | Buy | $6.00 from $7.00 | Nov 10, 2025 |
| Mizuho | Maintained | Neutral | $4.00 from $5.00 | Nov 6, 2025 |
| UBS | Maintained | Neutral | $4.00 from $4.25 | Nov 6, 2025 |
Frequently asked questions
What is the price target for GDRX stock?
The average 12-month analyst price target for Goodrx (GDRX) is $4.55, with a high estimate of $5.00 and a low of $3.75, across 5 analysts.
Is GDRX a buy, sell, or hold?
Analysts covering Goodrx currently average a Hold rating: 4 buy, 9 hold and 2 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for GDRX?
The average price target of $4.55 implies 30.75% upside from the last price of $3.48.
What is the latest analyst rating on GDRX?
On Aug 21, 2026, Barclays maintained Goodrx at Underweight with a price target of $4.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.